logo
I was diagnosed with terminal colon cancer after brushing off symptom that strikes millions after they eat

I was diagnosed with terminal colon cancer after brushing off symptom that strikes millions after they eat

Daily Mail​13-05-2025

Heather Candrilli had been suffering from bloating and stomach pain for years but blamed it on her diet and giving birth to two children. So, when she was diagnosed with stage 4 colon cancer, her world was turned upside down.
But the 36-year-old mother of two was determined to beat her diagnosis - which has a survival rate of 13 percent - and she 'hit the ground running' and started an aggressive chemotherapy regimen in May 2024.
But she's been been hit with painful side effects and medical bills that could exceed half a million dollars.
Her husband, Corey Candrilli, a disabled US Army combat veteran said: 'I don't understand exactly what she's going through, but I understand pain. I understand the highs and lows.
'She's amazing.'
Since her diagnosis, Mrs Candrilli has undergone 20 rounds of chemotherapy and multiple surgeries to try and remove tumors, but her fight isn't over.
Mr Candrilli said his wife's delayed diagnosis - she visited multiple doctors and had her symptoms dismissed - puts a spotlight on the need for a law that would require insurance companies to cover colonoscopies for younger patients with certain symptoms.
Colonscopies are the gold standard for screening for the disease, which is on the rise in young people across the US. They are typically recommended to begin at 45 and occur every 10 years so long as results are normal.
However, lack of - and confusion over - insurance coverage has led people to delay screening or has burdened them with bills for thousands of dollars.
On most insurance plans, the procedure should cost on average $79 out-of-pocket, with health insurers footing the rest of the about $2,125 bill.
But recently, patients have come forward to say they've been charged upward of $5,000, $7,000 and even $20,000 for the procedure, despite having health insurance.
The couple live in New York, where the law requires insurance coverage for colonoscopies only for people 45 and older.
'You can't get it. It's unbelievable,'' Mr Candrilli told SI Live of colonoscopies before 45.
'It's truly unbelievable. These are your teachers, your parents, people raising your children. These are our future.'
The army veteran said his wife had been experiencing bloating and abdominal pain but, 'when you're about that age, you're busy rising a family, and the last thing you're going to be thinking about is yourself.'
Mrs Candrilli was tested for the chronic autoimmune diseases crohn's and celiac, but the couple said a colonoscopy was never suggested.
However, an ultrasound of Mrs Candrilli's stomach detected something on her liver, then a colonoscopy was performed, which revealed an aggressively growing tumor that had spread to other parts of her body.
Mr Candrilli said: 'As soon as they ordered the colonoscopy, they saw the tumor right there on her colon.'
Mrs Candrilli underwent surgery to remove a portion of her colon and is now awaiting a liver transplant.
Since her initial surgery, she has undergone 20 rounds of chemotherapy, which her husband said are shrinking the tumors.
These sessions required her to spend four hours in the hospital every two weeks to receive the medication and then wear an external device that continued delivering chemotherapy to her for 48 hours after.
And while the treatments are working, Mr Candrilli said the family cannot keep up with medical bills.
He said: 'It's ridiculously expensive. Insurance is helpful, but we've been told that, even with insurance, this can go up to at least $500,000.'
A GoFundMe account has been set up to help the family with medical bills as Mrs Candrilli stopped working as a nanny before becoming a mother and supporting her husband after he suffered a traumatic brain injury in Iraq.
He told SI Live: 'She's the greatest medicine I've ever had my whole life.'
About 67 percent of adults adhere to current screening requirements, below the US government target of at least 70 percent.
Colon cancer often causes no symptoms until it has spread to other areas of the body, where it becomes harder to treat.
But warning signs can include trouble using the bathroom, blood in feces and persistent diarrhea or constipation.
Doctors fear that, faced with the risk of high prices, patients may put off any screenings — which can find pre-cancerous growths and eliminate them, slashing the risk of developing the cancer.
They may also put off screenings even when they have symptoms, risking the cancer reaching an advanced stage — making it harder to treat and deadlier.
Dr Glenn Littenberg, a physician who recently chaired the reimbursement committee of the American Society of Gastrointestinal Endoscopy, told DailyMail.com: 'The majority of people who do preventative screening should have very little out-of-pocket cost, regardless of where they go.
'But there are horror stories, with the exception being when someone goes out of network for their physical or hospital.'
'If patients are putting off colonoscopies worrying about costs, then this means these aren't removed.'
He added: 'Screening reveals benign polyps that aren't cancer, but by removing them we are reducing the risk of cancer developing.
'If you put off screening and don't do anything, there's certainly a much higher probability that when you go in, you have symptoms,' which may raise the risk of being diagnosed with cancer.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alzheimer's blood test can spot people with early symptoms, study suggests
Alzheimer's blood test can spot people with early symptoms, study suggests

The Guardian

time17 minutes ago

  • The Guardian

Alzheimer's blood test can spot people with early symptoms, study suggests

A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia by examining two proteins in blood plasma. The proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque buildup, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the journal Alzheimer's and Dementia, said the test was as good as more invasive tests in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who showed no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting,' he added. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline, though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US. We hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multimillion-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the National Health Service by 2029. Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40 and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'

Blood test for Alzheimer's disease is highly accurate, researchers say
Blood test for Alzheimer's disease is highly accurate, researchers say

Sky News

time4 hours ago

  • Sky News

Blood test for Alzheimer's disease is highly accurate, researchers say

Researchers say a new blood test for Alzheimer's disease has been shown to be highly accurate in detecting people with early symptoms. Scientists looked for two proteins - amyloid beta 42/40 and p-tau217 - and found the test was 95% accurate in identifying patients with existing cognitive impairment linked to the condition. The US study involved 509 patients in an outpatient memory clinic in Florida and was published in the medical journal Alzheimer's and Dementia. The test, which has already been approved by the US regulator, was also 82% accurate for specificity, which means it could rule out people without dementia. Dr Gregg Day, who led the study, said the test was as good as existing, but more invasive, tests. He said the next step was to extend the test to a wider range of patients, including those with early Alzheimer's who do not have any cognitive symptoms. Scientists say the two proteins, which they have identified in blood plasma, are associated with the buildup of amyloid plaques. Amyloid protein can be found in our brains, but in Alzheimer's disease, amyloid sticks together and forms abnormal deposits, which are thought to be toxic to brain cells. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results "suggest this test is very accurate". "Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before," he added. In the UK, the Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. 1:09 Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Julia Dudley, head of research at Alzheimer's Research UK, said: "We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal." She said the studies like the Blood Biomarker Challenge are a "crucial part of making diagnosis easier and faster, which will bring us closer to a cure". "The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK," she added.

Starmer goes all in on NHS with PM set to hand health service £30bn spending boost at expense of other public services
Starmer goes all in on NHS with PM set to hand health service £30bn spending boost at expense of other public services

Daily Mail​

time5 hours ago

  • Daily Mail​

Starmer goes all in on NHS with PM set to hand health service £30bn spending boost at expense of other public services

Sir Keir Starmer will pump money into the NHS at the expense of other public services. The government is putting all its eggs in one basket as it lines up the Department for Health for a £30billion cash boost at next week's spending review. However, health chiefs have warned the prime minister's promise to 'turbocharge delivery' could lead to difficult compromises elsewhere in services from the police to councils. It comes after the party's unexpected victory in the Hamilton, Larkhall & Stonehouse by-election - though as the threat of Nigel Farage 's Reform UK still looms large. The Department for Health will be handed an increase of around £200billion to its budget by 2028 - a £17billion rise in real terms. Its day-to-day budget is set to increase by 2.8 per cent in real terms annually over the three-year spending review period. Sir Keir has also pledged to have 92 per cent of NHS patients treated within 18 weeks by the next election, a target that has remained unmet for a decade. Currently, under 60 per cent are seen within this time with waiting lists rising to 7.4million last month. There are even fears NHS bosses may not hit an interim goal of 65 per cent next year. Chancellor Rachel Reeves' prioritisation of health has forced cuts in other departments and prompted protestations from other cabinet members like Yvette Cooper, the home secretary and Angela Rayner, the deputy prime minister and housing secretary. Both have warned Ms Reeves the cuts will put some of the government's crime and housing targets at risk amid 'robust negotiations'. But the chancellor has maintained 'not every department will get everything they want'. Overall, the health budget, which stood at £178billion as Labour took office, will exceed £230billion by the next election. The increase means health is set to account for 41 per cent of all day-to-day departmental spending - up from 39 per cent. Ben Zaranko, of the Institute for Fiscal Studies, said Ms Reeves's cash boost was 'a serious, meaningful increase in health funding'. But Matthew Taylor, chief executive of the NHS Confederation, warned the funding increase 'is not going to enable us to achieve recovery and reform' without big changes to the way the health service treats patients. He said the government's plan to withhold the budget for infrastructure simultaneously would also make 'combining recovery and reform' impossible.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store